Principal Financial Group Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,909,105 shares of the biopharmaceutical company’s stock after purchasing an additional 1,140,112 shares during the quarter. Principal Financial Group Inc. owned about 0.30% of Gilead Sciences worth $276,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Greenwood Capital Associates LLC lifted its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Greenwood Capital Associates LLC now owns 30,556 shares of the biopharmaceutical company’s stock valued at $2,163,000 after purchasing an additional 4,386 shares during the period. Contrarius Investment Management Ltd lifted its stake in shares of Gilead Sciences by 18.3% in the 2nd quarter. Contrarius Investment Management Ltd now owns 1,070,731 shares of the biopharmaceutical company’s stock valued at $75,786,000 after purchasing an additional 165,866 shares during the period. Ray Gerald L & Associates Ltd. lifted its stake in shares of Gilead Sciences by 10.8% in the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 83,092 shares of the biopharmaceutical company’s stock valued at $5,881,000 after purchasing an additional 8,067 shares during the period. Evergreen Capital Management LLC lifted its stake in shares of Gilead Sciences by 36.1% in the 2nd quarter. Evergreen Capital Management LLC now owns 42,880 shares of the biopharmaceutical company’s stock valued at $3,035,000 after purchasing an additional 11,385 shares during the period. Finally, Lipe & Dalton increased its position in Gilead Sciences by 30.0% in the 2nd quarter. Lipe & Dalton now owns 50,190 shares of the biopharmaceutical company’s stock valued at $3,552,000 after buying an additional 11,575 shares in the last quarter. 74.28% of the stock is currently owned by institutional investors.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-stake-lifted-by-principal-financial-group-inc/1679660.html.

GILD has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a research report on Wednesday, September 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.68.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.46 on Friday. The stock has a market capitalization of $96,012.22, a price-to-earnings ratio of 7.67, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a current ratio of 4.86, a quick ratio of 4.74 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.75 earnings per share. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other news, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 446,819 shares of company stock worth $36,269,486. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.